“Rising Prevalence of Chronic Skin Disorders”
The main reason for the growth of the dermatology small molecule API market is the rising prevalence of chronic skin disorders such as acne, psoriasis, eczema, and atopic dermatitis, coupled with increasing patient demand for more effective and affordable treatments. As these conditions become more common worldwide, there is a growing need for both topical and systemic therapies that can manage symptoms and improve quality of life.
Small molecule drugs are gaining traction due to their cost-effectiveness, accessibility, and proven efficacy, particularly in the treatment of mild to moderate skin conditions. For instance, topical retinoids such as tretinoin and corticosteroids remain first-line treatments for acne and psoriasis, offering patients targeted relief at a lower cost compared to biologics. Additionally, the development of newer, more advanced small molecule therapies, such as JAK inhibitors for inflammatory skin diseases, is expanding the treatment options available, fueling further market growth. The shift towards personalized dermatology treatments is also driving demand, with tailored therapies increasingly sought after.
